The approval of Calquence marks the first and only BTK inhibitor approved for the first-line treatment of MCL in the US.

Approval is based on results from the TROPION-Breast01 Phase III trial, in which Datroway demonstrated a significant reduction in the risk of disease progression or death in patients with previously ...

AstraZeneca AZN announced that the FDA has approved its antibody-drug conjugate (ADC), datopotamab deruxtecan (or Dato-DXd), ...

The FDA has approved AstraZeneca and Daiichi Sankyo’s Datroway (datopotamab deruxtecan-dlnk) to treat unresectable or ...

IonQ's strong revenue growth and partnerships with industry leaders are promising, but high operating expenses and reliance ...

Sir Chris Whitty tells the Covid-19 Inquiry the NHS has 'slipped backwards' since the pandemic at sharing vital patient data, ...

Sachin Jain, an analyst from Bank of America Securities, reiterated the Buy rating on AstraZeneca (AZN – Research Report). The associated price ...

British drug maker AstraZeneca Plc (AZN.L, AZN) and Daiichi Sankyo (DSKYF.PK) announced Monday that their Datroway (datopotamab ...

Funding for climate tech has contracted in recent years. What makes Gothenburg so unique in its ability to fund, scale and ...

Daiichi Sankyo shares rose sharply after the U.S. Food and Drug Administration approved its breast cancer drug Datroway. Shares were recently 8.7% higher at 4,437 yen, equivalent to $28.39, on Monday ...

AstraZeneca faces significant challenges amid Chinese investigation and ongoing investor lawsuit regarding alleged misconduct ...

Trapped-ion quantum computing leader IonQ (NYSE: IONQ) is emerging as a potential leader in the commercialization of quantum ...